These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

231 related articles for article (PubMed ID: 38845861)

  • 1. Pan-cancer analysis of the disulfidptosis-related gene
    Zong Y; Zhu A; Liu P; Fu P; Li Y; Chen S; Gao X
    Heliyon; 2024 Jun; 10(11):e31875. PubMed ID: 38845861
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Pan-cancer Analysis of the Disulfidptosis-related Gene NCKAP1 and Its Prognostic Value for Lung Adenocarcinoma.
    Zhu A; Zong Y; Wei S; Li Y; Fan Y; Liu S; Gao X
    J Cancer; 2023; 14(17):3351-3367. PubMed ID: 37928421
    [TBL] [Abstract][Full Text] [Related]  

  • 3.
    Wang X; Zhu HQ; Lin SM; Xia BY; Xu B
    Transl Cancer Res; 2024 May; 13(5):2518-2534. PubMed ID: 38881923
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Pan-cancer analysis of ubiquitin-specific protease 7 and its expression changes in the carcinogenesis of scar ulcer].
    Zhang SY; Ruan JJ; Jin DM; Chen N; Xie WG; Ruan QF
    Zhonghua Shao Shang Yu Chuang Mian Xiu Fu Za Zhi; 2023 Jun; 39(6):518-526. PubMed ID: 37805766
    [No Abstract]   [Full Text] [Related]  

  • 5. Comprehensive analysis of 33 human cancers reveals clinical implications and immunotherapeutic value of the solute carrier family 35 member A2.
    Xu S; Chen X; Fang J; Chu H; Fang S; Zeng L; Ma H; Zhang T; Chen Y; Wang T; Zhang X; Shen T; Zheng Y; Xu D; Lu Z; Pan Y; Liu Y
    Front Immunol; 2023; 14():1155182. PubMed ID: 37275857
    [TBL] [Abstract][Full Text] [Related]  

  • 6. A Pan-Cancer Analysis of the Oncogenic Role of
    Yang D; Li H; Chen Y; Li C; Ren W; Huang Y
    Front Genet; 2022; 13():906174. PubMed ID: 35910232
    [No Abstract]   [Full Text] [Related]  

  • 7. Identification of SHCBP1 as a potential biomarker involving diagnosis, prognosis, and tumor immune microenvironment across multiple cancers.
    Wang N; Zhu L; Wang L; Shen Z; Huang X
    Comput Struct Biotechnol J; 2022; 20():3106-3119. PubMed ID: 35782736
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Pan-Cancer Analysis of PARP1 Alterations as Biomarkers in the Prediction of Immunotherapeutic Effects and the Association of Its Expression Levels and Immunotherapy Signatures.
    Zhang X; Wang Y; A G; Qu C; Chen J
    Front Immunol; 2021; 12():721030. PubMed ID: 34531868
    [TBL] [Abstract][Full Text] [Related]  

  • 9. HHLA2 Used as a Potential Prognostic and Immunological Biomarker and Correlated with Tumor Microenvironment in Pan-Cancer.
    Yang Z; Xu D; Ye X; Lin X; Zhang M; Su Y; Xie Q; Ni W
    Biomed Res Int; 2022; 2022():3924400. PubMed ID: 35252444
    [TBL] [Abstract][Full Text] [Related]  

  • 10. MCM10 as a novel prognostic biomarker and its relevance to immune infiltration in gliomas.
    Tian QS; Zhang Q; Huang W
    Technol Health Care; 2023; 31(4):1301-1317. PubMed ID: 36872806
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Analysis of the potential biological value of pyruvate dehydrogenase E1 subunit β in human cancer.
    Rong Y; Liu SH; Tang MZ; Wu ZH; Ma GR; Li XF; Cai H
    World J Gastrointest Oncol; 2024 Jan; 16(1):144-181. PubMed ID: 38292838
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Pan-Cancer Integrated Analysis Identification of SASH3, a Potential Biomarker That Inhibits Lung Adenocarcinoma Progression.
    Chen X; Yuan Y; Ren W; Zhou F; Huang X; Pu J; Niu X; Jiang X
    Front Oncol; 2022; 12():927988. PubMed ID: 35756681
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Signature Construction and Disulfidptosis-Related Molecular Cluster Identification for Better Prediction of Prognosis in Glioma.
    Zhuang Y; Chen J; Mai Z; Huang W; Zhong W
    J Mol Neurosci; 2024 Apr; 74(2):38. PubMed ID: 38573391
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Differential Expression of the
    Hu J; Xu J; Feng X; Li Y; Hua F; Xu G
    Front Cell Dev Biol; 2021; 9():700661. PubMed ID: 34631699
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pan-cancer analysis predicts CANT1 as a potential prognostic, immunologic biomarker.
    Yang W; Liu Z; Liu T
    Cell Signal; 2024 May; 117():111107. PubMed ID: 38369265
    [TBL] [Abstract][Full Text] [Related]  

  • 16. Development of a novel disulfidptosis-related lncRNA signature for prognostic and immune response prediction in clear cell renal cell carcinoma.
    Wang N; Hu Y; Wang S; Xu Q; Jiao X; Wang Y; Yan L; Cao H; Shao F
    Sci Rep; 2024 Jan; 14(1):624. PubMed ID: 38182642
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Pan-Cancer Analysis and Experimental Validation of CEND1 as a Prognostic and Immune Infiltration-Associated Biomarker for Gliomas.
    Ma J; Lang B; Wang L; Zhou Y; Fu C; Tian C; Xue L
    Mol Biotechnol; 2024 Jun; ():. PubMed ID: 38836983
    [TBL] [Abstract][Full Text] [Related]  

  • 18. GLIPR2: a potential biomarker and therapeutic target unveiled - Insights from extensive pan-cancer analyses, with a spotlight on lung adenocarcinoma.
    Lin W; Zhang S; Gu C; Zhu H; Liu Y
    Front Immunol; 2024; 15():1280525. PubMed ID: 38476239
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Siglec-9, a Putative Immune Checkpoint Marker for Cancer Progression Across Multiple Cancer Types.
    Wu Y; Huang W; Xie Y; Wang C; Luo N; Chen Y; Wang L; Cheng Z; Gao Z; Liu S
    Front Mol Biosci; 2022; 9():743515. PubMed ID: 35372497
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Bioinformatics Analyses Reveal the Prognostic Value and Biological Roles of
    Zhang L; Zhao Q; Mao L; Li H; Zhuang M; Wang J; Liu Y; Qi M; Du X; Xia Z; Sun N; Liu Q; Chen H; Zhang R
    Int J Gen Med; 2021; 14():6059-6076. PubMed ID: 34594130
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 12.